Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 6 Squamous Cell Carcinoma of Head and Neck 2 Neoplasms 2 Melanoma 2 Lung Neoplasms 2 Head and Neck Neoplasms 2 Colorectal Neoplasms 2 Carcinoma, Squamous Cell 2 Uterine Cervical Neoplasms 1 Urothelial Cancer 1 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Spinocerebellar Degenerations 1 Solid Tumors 1 Solid Tumor, Adult 1 Small Cell Lung Carcinoma 1 Rectal Neoplasms 1 PD-L1-selected Solid Tumors 1 Glioblastoma 1 Carcinoma, Renal Cell 1 Carcinoma 1 Breast Neoplasms 1 Brain Neoplasms 1 Advanced Unresectable or Metastatic Solid Malignancy 1 Advanced Rare Malignant Solid Neoplasm 1

Interventions

Cisplatin 68 Paclitaxel 32 Radiotherapy 31 Carboplatin 23 Bevacizumab 21 pembrolizumab 20 Brachytherapy 18 atezolizumab 11 camrelizumab 10 Nivolumab 10 Gemcitabine 10 Drug Therapy 9 tislelizumab 8 Topotecan 8 Taxes 8 Chemoradiotherapy 8 Radiation 7 Docetaxel 7 Albumin-Bound Paclitaxel 7 zimberelimab 6 toripalimab 6 nimotuzumab 6 Magnetic Resonance Spectroscopy 6 Cetuximab 6 lenvatinib 5 durvalumab 5 dostarlimab 5 Platinum 5 Papillomavirus Vaccines 5 Injections 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Uterine Cervical Neoplasms × Tiragolumab × Clear all

NCT04300647 2026-03-12

SKYSCRAPER-04

Hoffmann-La Roche

Phase 2 Completed

172 enrolled 27 charts

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡